Search Results - "Fave, G"

Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells by Calabretta, S, Bielli, P, Passacantilli, I, Pilozzi, E, Fendrich, V, Capurso, G, Fave, G Delle, Sette, C

“…Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and incurable disease. Poor prognosis is due to multiple reasons, including acquisition of resistance…”
Get full text

ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms by Delle Fave, G, O'Toole, D, Sundin, A, Taal, B, Ferolla, P, Ramage, J K, Ferone, D, Ito, T, Weber, W, Zheng-Pei, Z, De Herder, W W, Pascher, A, Ruszniewski, P

Get more information

TNM Staging of Neoplasms of the Endocrine Pancreas: Results From a Large International Cohort Study by RINDI, G, FALCONI, M, DELLE FAVE, G, FISCHER, L, FUSAI, G, DE HERDER, W. W, JANN, H, KOMMINOTH, P, DE KRIJGER, R. R, LA ROSA, S, LUONG, T. V, PAPE, U, KLERSY, C, PERREN, A, RUSZNIEWSKI, P, SCARPA, A, SCHMITT, A, SOLCIA, E, WIEDENMANN, B, ALBARELLO, L, BONINSEGNA, L, BUCHLER, M. W, CAPELLA, C, CAPLIN, M, COUVELARD, A, DOGLIONI, C

“…Both the European Neuroendocrine Tumor Society (ENETS) and the International Union for Cancer Control/American Joint Cancer Committee/World Health Organization…”
Get full text

Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway by Adesso, L, Calabretta, S, Barbagallo, F, Capurso, G, Pilozzi, E, Geremia, R, Delle Fave, G, Sette, C

“…Pancreatic ductal adenocarcinoma (PDAC) is an aggressive neoplastic disease. Gemcitabine, the currently used chemotherapeutic drug for PDAC, elicits only minor…”
Get full text

Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases by Capurso, G., Rinzivillo, M., Bettini, R., Boninsegna, L., Fave, G. Delle, Falconi, M.

“…Background: Surgery for small intestinal neuroendocrine tumours (SI‐NETs) is limited by metastatic disease in most patients. However, resection of the primary…”
Get full text

Meta‐analysis of mortality in patients with high‐risk intraductal papillary mucinous neoplasms under observation by Vanella, G., Crippa, S., Archibugi, L., Arcidiacono, P. G., Delle Fave, G., Falconi, M., Capurso, G.

“…Background Although consensus guidelines suggest that patients with high‐risk intraductal papillary mucinous neoplasms (IPMNs) should have surgery, a…”
Get full text

ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms by Ramage, J K, De Herder, W W, Delle Fave, G, Ferolla, P, Ferone, D, Ito, T, Ruszniewski, P, Sundin, A, Weber, W, Zheng-Pei, Z, Taal, B, Pascher, A

Get more information

Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system by Öberg, K., Kvols, L., Caplin, M., Delle Fave, G., de Herder, W., Rindi, G., Ruszniewski, P., Woltering, E. A., Wiedenmann, B.

“…This consensus report gives a detailed description of the use of somatostatin analogs in the management of neuroendocrine tumors of the gastroenteropancreatic…”
Get full text

Prehospital triage of acute aortic syndrome using a machine learning algorithm by Duceau, B., Alsac, J.‐M., Bellenfant, F., Mailloux, A., Champigneulle, B., Favé, G., Neuschwander, A., El Batti, S., Cholley, B., Achouh, P., Pirracchio, R.

“…Background Acute aortic syndrome (AAS) comprises a complex and potentially fatal group of conditions requiring emergency specialist management. The aim of this…”
Get full text

Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours by Bettini, R., Boninsegna, L., Mantovani, W., Capelli, P., Bassi, C., Pederzoli, P., Delle Fave, G. F., Panzuto, F., Scarpa, A., Falconi, M.

“…Background: Non-functioning pancreatic endocrine tumours (NF-PETs) are an aggressive gastroenteropancreatic neoplasm. The present study assessed survival,…”
Get full text

Systematic review: impaired drug absorption related to the co‐administration of antisecretory therapy by LAHNER, E., ANNIBALE, B., DELLE FAVE, G.

“…Summary Background  Due to suppression of gastric acidity during antisecretory therapy, an impaired absorption of co‐administered drugs may occur. Aim  To…”
Get full text

Letter: investigating the intestinal mucosa‐associated microbiota – relevance and potential pitfalls by Pagnini, C., Delle Fave, G.

Get full text

European experts consensus statement on cystic tumours of the pancreas by Del Chiaro, Marco, Verbeke, Caroline, Salvia, Roberto, Klöppel, Gunter, Werner, Jens, McKay, Colin, Friess, Helmut, Manfredi, Riccardo, Van Cutsem, Eric, Löhr, Matthias, Segersvärd, Ralf

“…Abstract Cystic lesions of the pancreas are increasingly recognized. While some lesions show benign behaviour (serous cystic neoplasm), others have an…”
Get full text

Gastroenteropancreatic neuroendocrine tumours by Modlin, Irvin M, Prof, Oberg, Kjell, Prof, Chung, Daniel C, MD, Jensen, Robert T, MD, de Herder, Wouter W, MD, Thakker, Rajesh V, Prof, Caplin, Martyn, MD, Delle Fave, Gianfranco, Prof, Kaltsas, Greg A, MD, Krenning, Eric P, Prof, Moss, Steven F, MD, Nilsson, Ola, Prof, Rindi, Guido, MD, Salazar, Ramon, MD, Ruszniewski, Philippe, Prof, Sundin, Anders, MD

“…Summary Gastroenteropancreatic (GEP) neuroendocrine tumours (NETs) are fairly rare neoplasms that present many clinical challenges. They secrete peptides and…”
Get full text

Systematic review: Heliocobacter pylori infection and impaired drug absorption by LAHNER, E., ANNIBALE, B., DELLE FAVE, G.

“…Summary Background  Impaired acid secretion may affect drug absorption and may be consequent to corporal Heliocobacter pylori‐gastritis, which may affect the…”
Get full text

Thyroxine in Goiter, Helicobacter pylori Infection, and Chronic Gastritis by Centanni, Marco, Gargano, Lucilla, Canettieri, Gianluca, Viceconti, Nicola, Franchi, Antonella, Fave, Gianfranco Delle, Annibale, Bruno

“…This study, designed to determine whether impaired gastric acid secretion leads to an increased need for thyroxine in patients with euthyroid multinodular…”
Get full text

Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma by Obazee, O., Archibugi, L., Andriulli, A., Soucek, P., Małecka‐Panas, E., Ivanauskas, A., Johnson, T., Gazouli, M., Pausch, T., Lawlor, R. T., Cavestro, G. M., Milanetto, A. C., Di Leo, M., Pasquali, C., Hegyi, P., Szentesi, A., Radu, C. E., Gheorghe, C., Theodoropoulos, G. E., Bergmann, F., Brenner, H., Vodickova, L., Katzke, V., Campa, D., Strobel, O., Kaiser, J., Pezzilli, R., Federici, F., Mohelnikova‐Duchonova, B., Boggi, U., Lemstrova, R., Johansen, J. S., Bojesen, S. E., Chen, I., Jensen, B. V., Capurso, G., Pazienza, V., Dervenis, C., Sperti, C., Mambrini, A., Hackert, T., Kaaks, R., Basso, D., Talar‐Wojnarowska, R., Maiello, E., Izbicki, J. R., Cuk, K., Saum, K. U., Cantore, M., Kupcinskas, J., Palmieri, O., Delle Fave, G., Landi, S., Salvia, R., Fogar, P., Vashist, Y. K., Scarpa, A., Vodicka, P., Tjaden, C., Iskierka‐Jazdzewska, E., Canzian, F.

“…Rare truncating BRCA2 K3326X (rs11571833) and pathogenic CHEK2 I157T (rs17879961) variants have previously been implicated in familial pancreatic ductal…”
Get full text

Assessment of the Central Effects of Natural Uranium via Behavioural Performances and the Cerebrospinal Fluid Metabolome by Souidi, Maâmar, Martin, J. C., Dhieux, B., Elie, C., Favé, G., Grison, Stéphane, Lestaevel, Philippe, Tack, K.

“…Natural uranium (NU), a component of the earth’s crust, is not only a heavy metal but also an alpha particle emitter, with chemical and radiological toxicity…”
Get full text

Development and transferability of apricot and grape EST microsatellite markers across taxa by DECROOCQ, V, FAVE, M. G, HAGEN, L, BORDENAVE, L, DECROOCQ, S

“…EST microsatellite markers were developed in apricot (Prunus armeniaca L.) and grape (Vitis vinifera L.). cDNA libraries from either apricot leaves or grape…”
Get full text

Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS) by Plöckinger, U, Rindi, G, Arnold, R, Eriksson, B, Krenning, E P, de Herder, W W, Goede, A, Caplin, M, Oberg, K, Reubi, J C, Nilsson, O, Delle Fave, G, Ruszniewski, P, Ahlman, H, Wiedenmann, B

Get more information